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Background: Chronic myeloid leukemia is a myeloproliferative disorder characterized by the
Philadelphia chromosome or t(9;22)(q34.1;q11.2), resulting in the break-point cluster region-
Abelson tyrosine kinase fusion gene, which encodes a constitutively active tyrosine kinase
protein. The Philadelphia chromosome is detected by karyotyping in around 90% of chronic
myeloid leukemia patients, but 5–10% may have variant types. Variant Philadelphia chro-
mosomes are characterized by the involvement of another chromosome in addition to
chromosome 9 or 22. It can be a simple type of variant when one other chromosome is
involved, or complex, in which two or more chromosomes take part in the translocation. Few
studies have reported the incidence of variant Philadelphia chromosomes or the breakpoints
involved among Brazilian chronic myeloid leukemia patients.
Objective: The aim of this report is to describe the diversity of the variant Philadelphia chro-
mosomes found and highlight some interesting breakpoint candidates for further studies.
Methods: the Cytogenetics Section Database was searched for all cases with diagnoses of
chronic myeloid leukemia during a 12-year period and all the variant Philadelphia chromo-
somes were listed.
Results: Fifty (5.17%) cases out of 1071 Philadelphia-positive chronic myeloid leukemia were
variants. The most frequently involved chromosome was 17, followed by chromosomes: 1,
20,  6, 11, 2, 10, 12 and 15.
Conclusion: Among all the breakpoints seen in this survey, six had previously been described:
11p15, 14q32, 15q11.2, 16p13.1, 17p13 and 17q21. The fact that some regions get more  fre-
quently involved in such rare rearrangements calls attention to possible predisposition
that  should be further studied. Nevertheless, the pathological implication of these variants
remains unclear.
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Introduction
Chronic myeloid leukemia (CML) is a myeloproliferative
disorder characterized by the presence of the Philadel-
phia chromosome (Ph) which is the derivative chromosome
22 of the translocation t(9;22)(q34.1;q11.2). Due to this
rearrangement, the break-point cluster region (BCR) gene at
position 22q11.2 is juxtaposed to the c-Abelson (ABL1) gene at
9q34, resulting in the BCR-ABL1 fusion gene, encoding a con-
stitutively active tyrosine kinase protein. The identiﬁcation of
this abnormality is important for the diagnosis of the disease
as determined by the WHO  Tumor Classiﬁcation1 and for treat-
ment purposes. The ﬁrst therapeutic choice, tyrosine kinase
inhibitors, has shown great therapeutic efﬁcacy.2
The Ph is detected by G-band karyotyping in around 90% of
CML  patients among whom 5–10% may have variant types.3–5
Variant Ph chromosomes are characterized by the involve-
ment of another chromosome in addition to chromosome 9
or 22. It can be a simple type of variant when only one addi-
tional chromosome is involved, or complex, in which two or
more chromosomes, besides chromosomes 9 and 22, take part
in the translocation.6,7
Variant Ph breakpoints occur in hotspots across the
genome, usually in the G-light bands, within the cytosine and
guanine (CG) rich parts of the genome.4 CG content correlates
with chromatin condensation and transcription activity; that
is, open chromatin is transcriptionally active and relatively
likely to undergo breakage and repair with a consequent ten-
dency to illegitimate recombination and translocation.4 The
3′ portion of the BCR gene recombines preferentially with Alu
elements at the breaks.8 However, the mechanism of variant
Ph generation and the molecular bases of biological differ-
ences between classic Ph and variant Ph chromosomes are
not fully understood.9 Recently, Albano et al.10 reported a
study they performed on gene expression proﬁling (GEP) using
microarrays to identify some of these differences. They found
59 genes showing differential expressions. Some of them
(TR1B1, PTK2B and C5AR1)  were involved in the MAPK pathway,
which is already known to play a role in CML pathogenesis.
The prognostic signiﬁcance of variant Ph chromosomes has
already been discussed,11 and it has been shown that the vari-
ant aberration does not impact on cytogenetic or molecular
responses or even on clinical outcome.5
Variant Ph chromosomes are distinguished from addi-
tional chromosomal abnormalities or clonal evolution that
drives disease progression. The clonal evolution is a reﬂec-
tion of a genetic instability that characterizes the transition to
advanced phase.12 In this situation, i(17q), a second Ph and +8
are frequently found.
Few studies have reported the incidence of variant Ph
chromosomes, or the breakpoints involved, in Brazilian CML
patients.13,14
ObjectiveThe aim of this report is to describe the diversity of variant
Ph chromosomes found in a group of Brazilian CML  patientsr. 2 0 1 5;3 7(1):17–20
and to highlight some interesting breakpoint candidates for
further studies.
Methods
A search was conducted of variant Ph chromosomes among
all the cases of CML in the Cytogenetics Section Database of
Fleury Laboratory (São Paulo, Brazil), during a 12-year period
(from 1999 to 2010). The diagnosis of CML was made accord-
ing to WHO  Tumor Classiﬁcation,1 with analysis of complete
blood count, marrow aspiration and/or biopsy and karyotyp-
ing. Acute myeloid or lymphoid leukemia cases were excluded.
Karyotype analyses were performed from marrow samples,
through non-stimulated short term cultures and classiﬁed
according to the International System for Human Cytogene-
tics Nomenclature (ISCN).15 CML cases with positive BCR-ABL1
detection by ﬂuorescent in situ hybridization (FISH) or poly-
merase chain reaction (PCR) at diagnosis, but with cryptic
rearrangements by karyotyping, were excluded from the study
since they were cytogenetically invisible.
The study was approved by the Institution Ethics Commit-
tee.
Results
Fifty cases (5.17%) of variant t(9;22) were found out of 1071
Ph-positive CML. Table 1 shows the list of the variant Philadel-
phia translocation cases (some of these cases were previously
reported16) and Table 2 shows the rearrangement breakpoints.
A total of 33 different regions and almost all chromosomes
were involved in rearrangements, except for chromosomes: 8,
9, 18, 21, 22, X and Y. In two cases it was not possible to identify
the extra chromosome of the variant translocation.
Discussion
The incidence of variant Ph chromosomes in Brazilian CML
patients was similar to published data (5.17%).17 Forty-four
(88%) were simple variants and six (12%) complex (Table 1),
also in accordance with previous reports.4
The most frequently involved chromosome was 17 (eleven
times more  common in the present report), followed by chro-
mosome 1 (six times), 20 (ﬁve times), 6, 11 (four times each),
and 2, 10, 12 and 15 (three times each). Marzocchi et al.5
reported four cases of the involvement of chromosome 17 out
of 30 variants. The chromosomes not involved in Ph variant
translocations in the present study were: 8, 9, 18, 21, 22, X and
Y, while other studies have shown rearrangements of these
chromosomes, except for Y.14,17,18
Among all breakpoints seen in this survey, six were
repeated: 11p15, 14q32, 15q11.2, 16p13.1, 17p13 and 17q21, dif-
fering from the report by Marzocchi et al.5 who  did not ﬁnd any
recurrent breakpoints. On the other hand, Reid et al.19 listed
nine recurring breakpoints in variant Ph translocations, most
of which had been reported by others. In fact, it seems that
most breakpoints related to variant Ph chromosomes occur in
regions of known oncogenes or typical secondary breakpoints
in other types of cancer. Indeed, we endorse this statement,
since the current study also identiﬁed some breakpoints
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Table 1 – List of the variant Philadelphia translocations found.
Case Karyotype Type of translocation
1 46,XY,t(1;9;22;16)(q32;q34.1;q11.2;p13)[2]/46,XY Complex
2 46,XX,t(9;22;1;13)(q34.1;q11.2;p12;q34)[17]/46,XX[3] Complex
3 46,XY,t(9;22;1;?3)(q34.1;q11.2;q36.3;?q26)[20] Complex
4 46,XX,t(1;9;22;14)(p21;q34.1;q11.2;q32)[20] Complex
5 46,XX,t(9;22;1)(q34.1;q11.2;p34)[20] Simple
6 46,XX,t(9;22;1)(q34.1;q11.2;p36.3)[19]/46,XX[1] Simple
7 46,XX,t(9;22;2)(q34.1;q11.2;q37)[20] Simple
8 46,XY,t(2;9;22)(p21;q34.1;q11.2)[20] Simple
9 46,XY,t(9;22;2)(q34.1;q11.2;q24)[8]/46,XY[12] Simple
10 46,XY,t(9;22;4)(q34.1;q11.2;p16)[20] Simple
11 46,XY,t?(9;22;10;11)(q34.1;q11.2;q22;q25)[20] Complex
12 46,XY,t(9;22;5)(q34.1;q11.2;p13)[20] Simple
13 46,XY,t(9;22;6)(q34.1;q11.2;q22) Simple
14 46,XX,t(9;22;6)(q34.1;q11.2;q27)[7]/46,idem,?del(12)(p11.2p13)[3]/46,XX[10] Simple
15 46,XY,t(9;22;6)(q34.1;q11.2;q22) Simple
16 46,XY,t(9;22;15)(q34.1;q11.2;q11.2)[20] Simple
17 46,XX,t(9;22;7)(q34.1;q11.2;p22)[20] Simple
18 46,XX,t(?9;22;7)(q34.1;q11.2;q36), 9phqh[14]/46,XX, 9phqh[6] Simple
19 46,XY,t(9;22;10)(q34.1;q11.2;q21)[17]/46,XY[3] Simple
20 46,XY,t?(9;22;10;11)(q34.1;q11.2;q22;q25)[20] Complex
21 46,XY,t(9;22;4)(q34.1;q11.2;p16)[1]/45,idem,add(7)(p22),-8[18]/46,XY[1] Simple
22 44∼45,XX,t(7;12)(q11.2;p12),?t(9;22;11)(q34.1;q11.2;p15),-14,-
15,1min[cp18]/46,XX[2]
Simple
23 46,XY,t(9;22;11)(q34.1;q11.2;p15),9ph[20] Simple
24 46,XX,t(9;?22;12)(q34.1;?q11.2;q24)[17]/46,XX[3] Simple
25 46,XY,t(1;7)(p22;q22),t(9;22;20)(q34.1;q11;q11.2)[4]/46,XY,t(9;22;20)(q34.1;q11;q11.2)[3] Simple
26 46,XY,t(9;22;12)(q34.1;q11.2;p13)[20] Simple
27 46,XY,t(9;22;14)(q34.1;q11.2;q32)[19]/46,XY[1] Simple
28 46,XY,t(9;22;15)(q34.1;q11.2;q25),t(17;19)(q12;q13.4)[20] Simple
29 46,XY,t(9;22;15)(q34.1;q11.2;q11.2)[20] Simple
30 46,XX,t(9;22;6)(q34.1;q11.2;q27)[7]/46,idem,?del(12)(p11.2p13)[3]/46,XX[14] Simple
31 46,XX,t?(9;22;16)(q34.1;q11.2;p13.3)[20] Simple
32 46,XX,t(9;22;17)(q34.1;q11.2;q21?)[14]/46,XX[6] Simple
33 46,XX,t(9;22;17)(q34.1;q11.2;q?21)[16]/46,XX[4] Simple
34 46,XY,t(9;22;17)(q34.1;q11.2;q21)[20] Simple
35 46,XX,t(9;22;17)(q34.1;q11.2),t(12;13)(q13;p11)[20] Simple
36 46,XY,t(9;22;17)(q34.1;q11.2;p13)[20] Simple
37 46,XX,t(9;22;17)(q34.1;q11.2;q24)[20] Simple
38 46,XY,t(9;22;17)(q34.1;q11.2;p13)[20] Simple
39 46,XX,t(9;22;17)(q34.1;q11.2;q21)[10]//46,XX[10] Simple
40 46,XY,t(9;22;17)(q34.1;q11.2;p13)[3]/75∼77,XY,+X,+1,+5,+6,+9,t(9;22;17)(q34.1;q11.2;p13)x2,
+10,+11,+12,+20,+21,+22[cp16]/46,XY[1]
Simple
41 46,XX,t(9;22;17)(q34.1;q11.2;q24)[1]/47,XX,+8[8]/46,XX[11] Simple
42 46,XY,t(1;7)(p22;q22),t(9;22;20)(q34.1;q11;q11.2)[20] Simple
43 46,XY,t(9;22;19)(q34.1;q11.2;q11.2)[20] Simple
44 46,XY,t(9;22;20)(q34.1;q11.2;q11.2)[13]/46,XY,t(1;7)(p22;q22),idem[7] Simple
45 46,XY,t(1;7)(p22;q22),t(9;22;20)(q34.1;q11;q11.2)[2]/46,XY[18] Simple
46 46,XX,t(9;22;17)(q34.1;q11.2;q24)[1]/47,XX,+8[11]/46,XX[8] Simple
47 46,XY,t(9;22;12)(q34.1;q11.2;q24.3)[20] Simple
48 46,XY,t(1;7)(p22;q22),t(9;22;20)(q34.1;q11;q11.2)[1]/46,XY[9] Simple
49 46,XY,t(9;22;?)(q34.1;q11.2;?)[11]/46,XY[9] Simple
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ommon to other cancers, such as 12p13, 17p13 and 17q21.19
ome of the genes located in these regions are related to hema-
ological malignancies (i.e. ETV6, CD9, RARA, GAS7, IGH-2,
YB). However, additional genes have already been reported in
espect to CML, including TP53, located at 17p13, and involved
n up to 30% of CML  cases in blast crisis20 and MECOM and
RK1 that play a role in blast crises.21 Moreover, it is also
nown that the BCR-ABL1 tyrosine kinase activity activates the
13K/AKT signaling pathway.21 Thus, more  studies regardingSimple
the function, expression and regulation of these and other
genes may help to explain how variant Ph translocations
occur.
Controversies were found in respect to the meaning of
variant Ph chromosomes. Some authors have stated that the
involvement of additional oncogenes could be associated to
poorer prognosis although the European LeukemiaNet recom-
mendations do not provide advice for patients with variant
translocations.2,5 In the tyrosine kinase inhibitors era, it seems
20  rev bras hematol hemote
Table 2 – List of regions involved in Ph variant
translocations.
Chromosome region
1p34 2q37 10q21 15q11.2
1p36.3 3q26 10q22 15q25
1q11.2 4p16 11p15 16p13
1q12 5p13 11q25 17p13
1q32 6q22 12p13 17q21
1q36.3 6q27 12q24 17q24
r
1
1
1
1
1
1
1
1
1
1
2
22p21 7p22 13q34 19q11.2
2q24 7q36 14q32 20q11.2
that variant Ph translocations have no implication on the prog-
nosis, evolution of the disease and response to treatment.5,18
Conclusions
Due to the large variety of Ph variant translocations, it seems
that many  possible interactions exist with some occurring in
regions already reported as hotspots of oncogenes or related to
different types of cancer. This suggests that there must be local
phenomena favoring the predisposition to the involvement of
these breakpoints.
The incidence of Ph variant translocations in Brazilian
patients is similar to other reports worldwide however some
new variants were found. 17q21 was the most frequent and
repeated breakpoint and so this region is the most likely to be
involved in Ph variant translocations. Nevertheless, the patho-
logical implication of these variants remains unclear.
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